ATAI
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show consistent clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated good tolerability | ATAI
Company
Deck Type
Sector
Industry
Deck date
April 2023
Slide
10 of 30
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
March 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Investor Presentation
February 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Investor Presentation
January 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Investor Presentation
November 2022
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning and memory deficits no approved treatment a risked excellent tolerability | ATAI
Related slides by other companies
Equillium
Investor Presentation
February 2024
diversified pipeline of first in class immunology assets first class | Equillium
RayzeBio
IPO
September 2023
phase trial in first line combination treatment of | RayzeBio
Alkermes
Investor Day
March 2021
artistry determined selected as recommended phase dose for artistry efficacy expansion stage selection of based on totality of data including safety and efficacy during dose phase acceptable safety and tolerability profile consistent with the anticipated pharmacological effect and that observed with intravenous dose dependent increases in cell and cell activation and minimal increase in clinical benefit stable disease observed additional artistry data to be presented at future medical meeting phase efficacy expansion initiated based on totality of dose data regulatory cell natural killer pharmacodynamic | Alkermes
AN2 Therapeutics
IPO
March 2022
phase part a phase pivotal clinical in treatment refractory mac lung disease not i laced confirmed anticipated trial design during meeting with activities underway phase part seamless enrollment | AN2 Therapeutics
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io